AngioDynamics Inc. (NASDAQ: AGIO) – Q2 2026 Earnings Outlook
AngioDynamics Inc., a health‑care equipment and supplies company headquartered in Latham, New York, has announced that it will report financial results for the quarter ended 30 November 2025 (Q2 2026) on 6 January 2026. The company’s stock is traded on the Nasdaq and closed at $12.68 on 1 January 2026, with a 52‑week high of $13.99 and a low of $8.27. The market capitalisation stands at $522 million, and the price‑earnings ratio is negative at –16.2, reflecting a loss per share in the current fiscal year.
Analyst Expectations for the Quarter
Three analysts have provided consensus estimates for the upcoming earnings release:
| Metric | Consensus Estimate | YoY Comparison | Notes |
|---|---|---|---|
| Earnings per share (EPS) | –$0.10 | +61.5 % versus the prior‑year quarter (–$0.26) | Indicates a significant improvement in profitability. |
| Revenue | $76.4 M | +4.9 % versus the prior‑year quarter ( $72.8 M) | Modest revenue growth. |
| Full‑year EPS | –$0.33 | **+$0.5 ** versus the prior‑year loss of –$0.83 | Forecasted loss narrowing. |
| Full‑year revenue | $310.3 M | +$17.8 M versus the prior‑year $292.5 M | Expected increase in annual sales. |
The consensus EPS forecast of –$0.10 represents a 61.5 % improvement from the –$0.26 EPS reported in the same quarter a year earlier. Revenue is expected to rise by 4.9 % to $76.4 million, while the full‑year revenue projection of $310.3 million marks a 6.1 % increase over the previous year’s $292.5 million.
Market Sentiment and Options Activity
Prior to the earnings announcement, market participants have noted elevated options volatility for AngioDynamics, reflecting uncertainty surrounding the forthcoming results. The at‑the‑market straddle implied volatility is expected to rise in the days leading to the earnings release, a common pattern for companies with earnings expectations that deviate from historical performance.
Company Context
AngioDynamics specialises in therapeutic and diagnostic devices for interventional physicians, with product lines that include angiographic and hemodialysis catheters, image‑guided vascular access products, and thrombolytics. The company’s strategy focuses on designing, developing, manufacturing, and marketing devices that treat peripheral vascular and other non‑coronary diseases. Further information about the company and its products is available at www.angiodynamics.com .
The earnings report due on 6 January 2026 will provide the first concrete data to confirm whether the consensus forecasts translate into actual financial performance and will likely influence investor sentiment and subsequent trading activity for AngioDynamics Inc.
